Keros Therapeutics Inc

NASDAQ:KROS  
39.35
+1.60 (+4.24%)
Earnings Announcements

Keros Therapeutics Reports Recent Business Highlights And Second Quarter 2022 Financial Results

Published: 08/04/2022 20:58 GMT
Keros Therapeutics Inc (KROS) - Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results.
Keros Therapeutics Inc - Strengthened Cash Position and Extended Cash Runway to Fund Operations Into Q3 2024.
Keros Therapeutics Inc - Qtrly Loss per Share $1.13.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.23

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.20

More details on our Analysts Page.